LXJ-02
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


LXJ-02
Description :
LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin[1].UNSPSC :
12352209Target :
MMPType :
PeptidesRelated Pathways :
Metabolic Enzyme/ProteaseApplications :
Cancer-programmed cell deathField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/lxj-02.htmlSolubility :
10 mM in DMSOSmiles :
C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N1[C@H](C(N[C@H](C(N)=O)C)=O)CCC1)CO)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)C)=O)CO)(=O)[C@H]2N(C([C@@H](NC(CNC([C@@](NC([C@@H](NC(CCOCCOCCNC(CCOCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)[C@H](C)C)=O)(CC)C)=O)=O)CO)=O)CCC2Molecular Formula :
C94H159N19O34Molecular Weight :
2099.37References & Citations :
[1]Yixiang Wang, et al. Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment. J Med Chem. 2024 Apr 25;67 (8) :6624-6637.Shipping Conditions :
Room temperatureScientific Category :
PeptidesClinical Information :
No Development ReportedCAS Number :
[2672508-37-9]

